Wall Street Takes Downbeat View on Newly Public e-Commerce Stock

Morgan Stanley had some harsh words for JMIA stock

by Josh Selway

Published on May 7, 2019 at 3:10 PM

While Wall Street has been focused on other recent IPOs such as Lyft (LYFT) and Pinterest (PINS), Nigeria's Jumia Technology AG (NYSE:JMIA) also began trading in the U.S. last month. However, initial reviews on JMIA from analysts have mostly been negative, as we'll detail below.

RBC was the first to weigh in on the e-commerce stock, setting a tepid "sector perform" rating and $40 price target. A couple other firms have weighed in with the equivalent of a "hold" recommendation, as well, but Morgan Stanley has a much more bearish outlook. 

Specifically, analysts there released a note that gave JMIA stock an "underweight" rating and $27 price target, while raising concerns about the fact that only about half of active buyers return to the platform over the next year. Morgan Stanley attributes the low retention rates to the immaturity of the market, and says the shares' current price doesn't reflect the uncertainty around the company.

This note is likely the reason Jumia Technology is trading down 6.8% today at $35.16, on pace for its fourth straight down day. The stock opened for trade at $18.95 back on April 12, and eventually went as high as $49.77 a few days later. The company's market cap currently comes in at $2.7 billion, after bringing in $130.6 million in revenue in 2018.


a schaeffer's exclusive

PLAY TRENDS LIKE A PRO!

5 tips to leverage profits in this FREE insider report!


 
 

Partnercenter


NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories


The Trend Minting Millionaires -- But Who Is Really Paying?
Porter Stansberry is making a concerning prediction.
Wall Street Reacts to Fed Decision, Trade Deal
Investors waited and reacted to the Fed decision and trade headlines
Sarepta Therapeutics Stock Eyes Best Day in 3 Years on FDA Reversal
SRPT is buzzing on the FDA's change of heart
The Trend Minting Millionaires -- But Who Is Really Paying?
Porter Stansberry is making a concerning prediction.